Vaccines | Page 7 of 21 | Links Medicus Content Curation & Alerts in Medicine

🆕 Summary of WHO recommendations on #COVID19 vaccination in pregnancy https://t.co/XPVggBbSmj

If you’re pregnant, vaccination is one of the most important ways to protect yourself and your baby from severe illness from COVID-19. pic.twitter.com/dfSBVJLBG7

— World Health Organization (WHO) (@WHO) February 15, 2022

Covid-19: Vaccination during pregnancy is safe, finds large US study.

16 Feb, 2022 | 09:51h | UTC

Covid-19: Vaccination during pregnancy is safe, finds large US study – The BMJ

Original Study: Receipt of COVID-19 Vaccine During Pregnancy and Preterm or Small-for-Gestational-Age at Birth — Eight Integrated Health Care Organizations, United States, December 15, 2020–July 22, 2021 – CDC Morbidity and Mortality Weekly Report

COVID vaccines safely protect pregnant people: the data are in.

COVID-19 vaccination in pregnancy—number needed to vaccinate to avoid harm.

A case-controlled study showed Covid-19 vaccination during early pregnancy was not associated with increased risk of first-trimester miscarriage.

Editorial: Covid-19 treatments and vaccines must be evaluated in pregnancy.

AstraZeneca vaccination not linked to reduced fertility rates and adverse birth outcomes.

Cohort study: Vaccinated pregnant patients had 90% lower risk of severe or critical Covid-19 compared with unvaccinated pregnant patients.

Two observational studies suggest spontaneous abortion is not increased following COVID-19 mRNA vaccination during pregnancy.

Study shows high effectiveness of the Pfizer mRNA COVID-19 vaccine in pregnancy.

5 Crucial Things to Know About COVID-19 Vaccines and Pregnancy.

CDC Guidance: Pregnant people should be vaccinated against COVID-19.

ACOG and SMFM Recommend COVID-19 Vaccination for Pregnant Individuals – “ACOG encourages its members to enthusiastically recommend vaccination to their patients.”

Cohort study: Pfizer/BioNTech COVID vaccine associated with 78% lower risk of Covid-19 in pregnancy.

Omicron-targeted vaccines do no better than original jabs in early tests in animals.

15 Feb, 2022 | 10:09h | UTC

Omicron-targeted vaccines do no better than original jabs in early tests – Nature

Meta-analysis of randomized clinical trials: vaccines to prevent COVID-19.

15 Feb, 2022 | 10:04h | UTC

Vaccines to prevent COVID-19: A living systematic review with Trial Sequential Analysis and network meta-analysis of randomized clinical trials – PLOS One

Covid-19: Fourth vaccine doses—who needs them and why?

15 Feb, 2022 | 09:59h | UTC

Covid-19: Fourth vaccine doses—who needs them and why? – The BMJ

Novavax says protein vaccine works for kids as young as 12.

13 Feb, 2022 | 22:54h | UTC

Novavax says protein vaccine works for kids as young as 12 – Associated Press

Press Release: Novavax Announces Positive Results of COVID-19 Vaccine in Pediatric Population of PREVENT-19 Phase 3 Clinical Trial

Randomized trial with nearly 30.000 individuals showed Novavax vaccine was safe and had an overall efficacy of 90.4% against symptomatic infections.

RCT: Novavax vaccine conferred 89.7% protection against symptomatic SARS-CoV-2 infection and 100% protection against hospitalizations or deaths.

Opinion | The mRNA vaccines are extraordinary, but Novavax is even better.

(Press release – not published yet) Novavax COVID-19 vaccine demonstrates 90% overall efficacy and 100% protection against moderate and severe disease.

RCT: Novavax vaccine is 49.4% effective against B.1.351 SARS-CoV-2 variant.

[Press release – not published yet] Novavax reports 96% efficacy against original strain of COVID-19, 86% efficacy against B.1.1.7 variant, and 55% efficacy against B1.351 variant

New COVID-19 vaccines: here’s how the promising Novavax and Johnson & Johnson jabs work

Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant

RCT: Final analysis of efficacy and safety of single-dose J&J vaccine.

10 Feb, 2022 | 10:03h | UTC

Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S – New England Journal of Medicine

Commentary on Twitter

A single injection of the Ad26.COV2.S Covid-19 vaccine showed 56.3% vaccine efficacy beginning 14 days after injection and 52.9% efficacy more than 28 days after injection against moderate to severe–critical #COVID19. #IDTwitter https://t.co/0VhaEUtmwq pic.twitter.com/04QqSyYwNI

— NEJM (@NEJM) February 9, 2022

[Preprint] Post-marketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12-39 years in Italy.

9 Feb, 2022 | 10:08h | UTC

Post-marketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12-39 years in Italy: a multi-database, self-controlled case series study -medRxiv

Myocarditis after BNT162b2 vaccination in Israeli adolescents.

Myocarditis cases reported after mRNA-Based COVID-19 vaccination in the US from December 2020 to August 2021.

A case-control study showed an increased risk of myocarditis after COVID-19 vaccination with a messenger RNA vaccine compared to an inactivated virus vaccine.

[Preprint] Risk of myocarditis following sequential COVID-19 vaccinations by age and sex.

Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination vs. SARS-CoV-2 infection.

Case series with 139 adolescents and young adults with suspected myocarditis following mRNA vaccination showed most cases had a mild clinical course and rapid resolution of symptoms.

Heart-inflammation risk from Pfizer COVID vaccine is very low.

Large cohort study with over 2.5 million individuals showed the incidence of myocarditis after the Pfizer vaccine was 2.13 cases per 100,000 persons.

Study with over 5.1 million vaccinated individuals showed the incidence of myocarditis after the receipt of the Pfizer vaccine was low and more common after the second dose in young male recipients.

Large Observational study shows Pfizer Covid vaccine is mostly safe but is associated with increased risk of myocarditis, adenopathy, appendicitis, and herpes zoster.

Commentary on Twitter

The incidence of mRNA vaccine myocarditis or pericarditis in Italy in ~3 million vaccinees age 12-39. Excess cases per 100,000; orange is 2nd dose, blue 1st dose. https://t.co/xvdV4qSdHw
Pfizer:~1/100,000 age 12-39, all 2nd dose
Moderna,: >5/100,000, age 12-39, and some 1st dose pic.twitter.com/Y1jfGrU53v

— Eric Topol (@EricTopol) February 9, 2022

Systematic Review: Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations.

9 Feb, 2022 | 10:02h | UTC

Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review – Clinical Microbiology and Infection

Perspective | Three, four or more: what’s the magic number for booster shots?

8 Feb, 2022 | 10:03h | UTC

Three, four or more: what’s the magic number for booster shots? – Nature

First patients vaccinated in clinical trial of HIV experimental vaccine that uses Moderna’s mRNA technology.

4 Feb, 2022 | 08:25h | UTC

First patients vaccinated in clinical trial of HIV experimental vaccine that uses Moderna’s mRNA technology – CNN

Editorial: Menstruation and Covid-19 vaccination.

2 Feb, 2022 | 08:46h | UTC

Menstruation and covid-19 vaccination – The BMJ

News Release: New studies provide reassuring data on menstrual changes after covid-19 vaccination – BMJ

Commentary on Twitter

The findings from two new studies are reassuring: "changes to the menstrual cycle do occur following vaccination, but they are small compared with natural variation and quickly reverse"https://t.co/QFZ4I1U6yd

— The BMJ (@bmj_latest) January 28, 2022

Ten billion COVID vaccinations: world hits new milestone.

2 Feb, 2022 | 08:48h | UTC

Ten billion COVID vaccinations: world hits new milestone – Nature

Commentary on Twitter

10 billion doses given, <1 billion were boosters
1 continent nearly left outhttps://t.co/DrCqQ4b7tJ
and @OurWorldInData

“It is a huge scientific achievement that ten billion doses of vaccines to a new pathogen were developed in two years from its identification”—@doctorsoumya pic.twitter.com/pyLXlvI22Q

— Eric Topol (@EricTopol) February 1, 2022

Short Review | Hypersensitivity reactions to vaccines in children: from measles to SARS-CoV-2.

2 Feb, 2022 | 08:13h | UTC

Hypersensitivity reactions to vaccines in children: from measles to SARS-CoV-2 – Pediatric Allergy and Immunology

Commentary: Vaccine hypersensitivity in children – News Medical

Does the world need an Omicron vaccine? What researchers say.

1 Feb, 2022 | 08:53h | UTC

Does the world need an Omicron vaccine? What researchers say – Nature

The extraordinary success of Covid-19 vaccines, in two charts.

1 Feb, 2022 | 08:48h | UTC

The extraordinary success of Covid-19 vaccines, in two charts – Vox

Studies show parental vaccination provided indirect protection of children from SARS-CoV-2 infection during the Delta wave.

30 Jan, 2022 | 14:52h | UTC

Indirect protection of children from SARS-CoV-2 infection through parental vaccination – Science

Commentary: COVID vaccine markedly cuts household transmission, studies show – CIDRAP

Commentary on Twitter

Just published @Science
2 reports on the indirect protection of children via vaccination of parents in households
Marked level of effectiveness during Delta wave in Israel for prevention of infectionhttps://t.co/mjDHNYfbBA https://t.co/l2XjvFuvgC pic.twitter.com/Qq3ZDqxhqg

— Eric Topol (@EricTopol) January 27, 2022

Observational analysis in Lombardy, Italy, showed a gradual decrease in protection against SARS-CoV-2 clinical outcomes after the second dose of vaccine.

30 Jan, 2022 | 14:51h | UTC

Persistence of protection against SARS-CoV-2 clinical outcomes up to 9 months since vaccine completion: a retrospective observational analysis in Lombardy, Italy – The Lancet Infectious Diseases

Commentary: COVID-19 vaccine: what are we doing and what should we do? – The Lancet Infectious Diseases

Myocarditis after BNT162b2 vaccination in Israeli adolescents.

30 Jan, 2022 | 14:34h | UTC

Myocarditis after BNT162b2 Vaccination in Israeli Adolescents – New England Journal of Medicine

Myocarditis cases reported after mRNA-Based COVID-19 vaccination in the US from December 2020 to August 2021.

A case-control study showed an increased risk of myocarditis after COVID-19 vaccination with a messenger RNA vaccine compared to an inactivated virus vaccine.

[Preprint] Risk of myocarditis following sequential COVID-19 vaccinations by age and sex.

Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination vs. SARS-CoV-2 infection.

Case series with 139 adolescents and young adults with suspected myocarditis following mRNA vaccination showed most cases had a mild clinical course and rapid resolution of symptoms.

Heart-inflammation risk from Pfizer COVID vaccine is very low.

Large cohort study with over 2.5 million individuals showed the incidence of myocarditis after the Pfizer vaccine was 2.13 cases per 100,000 persons.

Study with over 5.1 million vaccinated individuals showed the incidence of myocarditis after the receipt of the Pfizer vaccine was low and more common after the second dose in young male recipients.

Large Observational study shows Pfizer Covid vaccine is mostly safe but is associated with increased risk of myocarditis, adenopathy, appendicitis, and herpes zoster.

Commentary on Twitter

Data from the Israeli MOH show estimates of myocarditis risk in the 21 days after a first & second dose of vaccine were 0.56 per 100,000 and 8.09 per 100,000 among male recipients and 0 per 100,000 and 0.69 per 100,000 among females. https://t.co/M6kxVA2toS pic.twitter.com/bQ4TBmcrj4

— NEJM (@NEJM) January 29, 2022

RCT: Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination.

28 Jan, 2022 | 08:37h | UTC

Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial – Nature Medicine

RCT: Heterologous (Pfizer, J&J, or AstraZeneca) vs. homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil.

Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination – Nature Medicine

WHO issues interim recommendations for heterologous COVID-19 vaccine schedules.

Italian lab study finds Sputnik V beat Pfizer’s mRNA vaccine against Omicron – yielding higher antibody levels.

27 Jan, 2022 | 09:47h | UTC

Italian Lab Study Finds Sputnik V Beat Pfizer’s mRNA Vaccine Against Omicron – Yielding Higher Antibody Levels – Health Policy Watch

RCT: Heterologous (Pfizer, J&J, or AstraZeneca) vs. homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil.

26 Jan, 2022 | 02:30h | UTC

Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study – The Lancet

Commentaries:

Boosting immunity after CoronaVac – The Lancet

Covid-19: CoronaVac immunity is strongest after boosting with a different vaccine – The BMJ

Commentary on Twitter

Heterologous boosting after 2 doses of #CoronaVac COVID-19 vaccine results in more robust immune responses than homologous boosting, study suggests. https://t.co/845JFnn3t7 pic.twitter.com/ibT3b5rs2K

— The Lancet (@TheLancet) January 23, 2022